Robert L. Glanzman

Neurology

34 Dutch Hill Dr
Carmel, NY 10512

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

Journal: JAMA

Published: March 11, 2025

Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials.

Correction: Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM- Au8, in the REPAIR phase 2 clinical trials.

Journal: Journal of nanobiotechnology

Published: January 03, 2024

Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.

Evidence of brain target engagement in Parkinson's disease and multiple sclerosis by the investigational nanomedicine, CNM-Au8, in the REPAIR phase 2 clinical trials.

Journal: Journal of nanobiotechnology

Published: November 03, 2023

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.

Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension.

Journal: EClinicalMedicine

Published: February 20, 2023

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 09, 2021

Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment.

Gold Coast diagnostic criteria: Implications for ALS diagnosis and clinical trial enrollment.

Journal: Muscle & nerve

Published: June 21, 2021

Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease.

Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease.

Journal: Journal of the neurological sciences

Published: April 09, 2021

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression.

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression.

Journal: BMJ open

Published: January 12, 2021

Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017.

Prehistoric enemies within: The contribution of human endogenous retroviruses to neurological diseases. Meeting report: "Second International Workshop on Human Endogenous Retroviruses and Disease", Washington DC, March 13th and 14th 2017.

Journal: Multiple sclerosis and related disorders

Published: April 26, 2017

A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.

A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.

Journal: Multiple sclerosis and related disorders

Published: June 30, 2016

EDSS variability before randomization may limit treatment discovery in primary progressive MS.

EDSS variability before randomization may limit treatment discovery in primary progressive MS.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: October 03, 2012

On being a neurologist in industry.

On being a neurologist in industry.

Journal: Annals of neurology

Published: June 06, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026